Clinical trials: Carrier State
- Condition Carrier State
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Strept Throat
Rapid Strep Test Results
This is a prospective study seeks to determine how often a rapid antigens test for group A streptococcus is positive in healthy adults
- Trial name
- NCT04256694
- Testing
- Rapid Antigen Test for Group A Streptococcus
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Kendall Healthcare Group, Ltd.
SARS-CoV2 Infection
Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein
This is Phase 1 study is to assess tolerability and immunogenicity of three dose levels of the investigational HDT-301 vaccine administered intramuscularly (IM), both in immunization-naïve participants and as a booster for those…
- Trial name
- NCT05132907
- Testing
- HDT-301
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HDT Bio
Hereditary Amyloidosis, Transthyretin-Related, Asymptomatic Carrier State
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR…
- Trial name
- NCT06360289
- Testing
- Standard of Care
- Where
- France
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Healthy
The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers
The study objective is to determine the effect of the ethanolic solutions inhaled from the Metered dose inhaler (MDI) (15.5 mg, 31.2 mg and 62.4 mg of ethanol) and from Respimat® (18.4 of ethanol) on the breath alcohol…
- Trial name
- NCT02264145
- Testing
- Ethanolic Solution From HFA134a-MDI - low, Ethanolic Solution From HFA134a-MDI - medium, Ethanolic Solution From HFA134a-MDI - high
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Infectious Disease, Bacterial Infections
Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients
The purpose of this study is to determine whether the antibacterial protein P128 is (i) safe and well tolerated in healthy volunteers and in chronic kidney diseases patients on dialysis, (ii) is it effective in reducing the nasal…
- Trial name
- NCT01746654
- Testing
- P128-0.1 mg, P128-0.3 mg, P128-1.0 mg
- Where
- Singapore
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GangaGen, Inc.
Respiratory Syncytial Viral Infections
Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine
The study is a double-blind (within dose level), placebo-controlled Phase I study to assess the safety, reactogenicity and tolerability of two intranasal dose levels of SynGEM®: a low dose level (140 μg F-protein/2mg BLPs) and a…
- Trial name
- SynGEM (NCT02958540)
- Testing
- SynGEM
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mucosis BV
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
- Trial name
- NCT01123941
- Testing
- Typherix, NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis
COVID-19, COVID-19 Vaccine
Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine
A multicenter, randomized, double-blind, active comparator, non-inferiority, multicenter IIb clinical trial to compare the safety and immunogenicity of two dose levels of the MCTI CIMATEC HDT RNA Vaccine against two authorized…
- Trial name
- NCT05542693
- Testing
- RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Genetic Disease
Digital Genetic Assistant (DGA) for Expanded Carrier Screening
The DGA provides an end-to-end digital solution to the preconception carrier screening process from participant registration to receipt of the test results and their interpretations.
- Trial name
- NCT04248504
- Testing
- Digital Genetic Assistant
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Igentify Ltd
Diagnoses Disease
Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings
Sickle cell disease is a life-threatening genetic disorder that can be effectively treated following early diagnosis via newborn screening.
- Trial name
- NCT03619798
- Testing
- HemoTypeSC
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Silver Lake Research Corporation
Vaccine, Crimean-Congo Hemorrhagic Fever
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
The goal of this clinical trial is to assess the safety, tolerability and immunogenicity of three dosage levels, and a single or two-dose administration regimen, of the investigational HDT-321 product administered…
- Trial name
- NCT06799013
- Testing
- 10 ug HDT 321, 25ug HDT-321, 50ug HDT-321
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HDT Bio